IMO is excited to announce that it has acquired Melax Technologies, Inc (Melax Tech), a data analytics and business intelligence company that empowers the healthcare and life science industry to use artificial intelligence (AI) and natural language processing (NLP) technology to extract information from biomedical textual data to help solve real-world problems.
The acquisition of Melax Tech will enhance IMO’s portfolio of healthcare data solutions and enable IMO to expand its offerings to provide clients with deeper insights into their clinical operations, and to improve patient outcomes as well as reduce overall costs.
“Today marks an exciting moment for IMO as we complete our first acquisition,” said Ann Barnes, Chief Executive Officer at IMO. “Combining Melax Tech’s analytics and NLP capabilities with IMO’s clinical terminology and data quality platform will enable healthcare organizations to have a more comprehensive solution for both clinical operation and research. The acquisition will also help extend our state-of-the-art capabilities to payer, pharmaceutical, and life science companies.”